Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition

被引:13
|
作者
Ziogos, Efthymios [1 ]
Chelko, Stephen P. [1 ,2 ]
Harb, Tarek [1 ]
Engel, Morgan [2 ]
Vavuranakis, Michael A. [1 ]
Landim-Vieira, Maicon [2 ]
Walsh, Elise M. [3 ,4 ]
Williams, Marlene S. [1 ]
Lai, Shenghan [5 ]
Halushka, Marc K. [3 ]
Gerstenblith, Gary [1 ]
Leucker, Thorsten M. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, 600 North Wolfe St, Baltimore, MD 21287 USA
[2] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, 600 North Wolfe St, Baltimore, MD 21287 USA
[4] Johns Hopkins Univ, Sch Med, Dept Genet Med, 600 North Wolfe St, Baltimore, MD 21287 USA
[5] Univ Maryland, Sch Med, Inst Human Virol, Dept Epidemiol & Publ Hlth, 660 Redwood St, Baltimore, MD 21201 USA
关键词
PCSK9; Platelets; Endothelial Cells; ACS; inhibition; SUBTILISIN/KEXIN TYPE 9; VON-WILLEBRAND-FACTOR; EARLY POSTINFARCTION PERIOD; PLATELET-FACTOR-4; EXPRESSION; SELECTIN; MARKERS; DISEASE;
D O I
10.1093/ehjcvp/pvad051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Platelet activation and endothelial dysfunction contribute to adverse outcomes in patients with acute coronary syndromes (ACS). The goals of this study were to assess the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition on markers of platelet activation and endothelial dysfunction in ACS patients and the interaction among PCSK9, platelets, and endothelial cells (ECs) on left internal mammary artery (LIMA) vascular endothelium using specimens obtained during coronary arter y bypass surgery (CABG). Methods and Results Acute coronary syndromes patients enrolled in the Evolocumab in ACS trials were randomized to placebo or a single dose of 420 mg evolocumab within 24 h of hospitalization. Serum samples for analysis of platelet factor 4 (PF4) and P-selectin, markers of platelet activation, and von Willebrand factor (vWF), a marker of endothelial dysfunction, were obtained at baseline and 30 days. Additionally, LIMA segments obtained during CABG from patients who were and were not receiving evolocumab were immunostained with PCSK9; CD61, a platelet-specific marker; and CD31, an endothelial cell-specific marker. Forty-six participants were randomized to placebo or to evolocumab. Controlling for baseline levels, PF4 and vWF were significantly lower in the evolocumab, than in the placebo, group at 30 days. Immunostaining of LIMA specimens from twelve participants undergoing CABG revealed colocalization of PCSK9, CD61, and CD31 at the vascular endothelium. Administration of evolocumab was associated with decreased overlap of PCSK9, CD61, and CD31. Conclusions Proprotein Convertase Subtilisin/Kexin 9 inhibition decreases markers of platelet activation and endothelial dysfunction in ACS patients. PCSK9 is associated with platelets and vascular ECs in LIMA segments and PCSK9 inhibition decreases that interaction. [GRAPHICS]
引用
收藏
页码:636 / 646
页数:11
相关论文
共 50 条
  • [21] Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)
    Puri, Rishi
    Nissen, Steven E.
    Somaratne, Ransi
    Cho, Leslie
    Kastelein, John J. P.
    Ballantyne, Christie M.
    Koenig, Wolfgang
    Anderson, Todd J.
    Yang, Jingyuan
    Kassahun, Helina
    Wasserman, Scott M.
    Scott, Robert
    Borgman, Marilyn
    Nicholls, Stephen J.
    AMERICAN HEART JOURNAL, 2016, 176 : 83 - 92
  • [22] PCSK9 inhibition 2018: riding a new wave of coronary prevention
    Ward, Natalie C.
    Page, Michael M.
    Watts, Gerald F.
    CLINICAL SCIENCE, 2019, 133 (02) : 205 - 224
  • [23] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)
    Ziogos, E.
    Harb, T.
    Valenta, I.
    Vavuranakis, M. A.
    Williams, M. S.
    Blaha, M. J.
    Jones, S. R.
    Schindler, T. H.
    Gerstenblith, G.
    Leucker, T. M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [24] PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
    Sun, Hua
    Krauss, Ronald M.
    Chang, Jeffrey T.
    Teng, Ba-Bie
    JOURNAL OF LIPID RESEARCH, 2018, 59 (02) : 207 - 223
  • [25] PCSK9 as a predictor of cardiovascular events in atrial fibrillation: role of platelet activation
    Carnevale, R.
    Cammisotto, V.
    Nocella, C.
    Bartimoccia, S.
    Pastori, D.
    Violi, F.
    Pignatelli, P.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3338 - 3338
  • [26] Prognostic value of PCSK9 levels in patients with acute coronary syndromes
    Gencer, B.
    Montecucco, F.
    Nanchen, D.
    Carbone, F.
    Klingenberg, R.
    Vuilleumier, N.
    Aghlmandi, S.
    Heg, D.
    Raeber, L.
    Jueni, P.
    Windecker, S.
    Luescher, T. F.
    Matter, C. M.
    Rodondi, N.
    Mach, F.
    EUROPEAN HEART JOURNAL, 2016, 37 : 143 - 143
  • [27] Role of PCSK9 Inhibitors in Acute Coronary Syndromes - A Pilot Study
    Abdelnabi, Mahmoud
    Benjanuwattra, Juthipong
    Saleh, Yehia
    Del Rio-Pertuz, Gaspar
    Leelaviwat, Natnicha
    Almaghraby, Abdallah
    CIRCULATION, 2022, 146
  • [28] Prognostic value of PCSK9 levels in patients with acute coronary syndromes
    Gencer, Baris
    Montecucco, Fabrizio
    Nanchen, David
    Carbone, Federico
    Klingenberg, Roland
    Vuilleumier, Nicolas
    Aghlmandi, Soheila
    Heg, Dik
    Raeber, Lorenz
    Auer, Reto
    Jueni, Peter
    Windecker, Stephan
    Luescher, Thomas F.
    Matter, Christian M.
    Rodondi, Nicolas
    Mach, Francois
    EUROPEAN HEART JOURNAL, 2016, 37 (06) : 546 - 553
  • [29] The benefits of PCSK9 inhibitors in patients with acute coronary syndrome:a systematic review and meta-analysis
    Guanzhao Zhang
    Shuting Chang
    Faming Zhao
    Xiangfeng Guan
    Zifan Nie
    Wenhao Liu
    Bo Li
    Emergency and Critical Care Medicine, 2024, 4 (01) : 28 - 34
  • [30] Biomarkers of platelet activation in acute coronary syndromes
    Ferroni, Patrizia
    Riondino, Silvia
    Vazzana, Natale
    Santoro, Nicole
    Guadagni, Fiorella
    Davi, Giovanni
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (06) : 1109 - 1123